The Conversation (0)
Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
Jun. 04, 2018 08:53AM PST
Biotech InvestingMersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating the Company’s investigational compound, XMT-1522. As quoted in the press release: …
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating the Company’s investigational compound, XMT-1522.
As quoted in the press release:
“We are highly encouraged by these first clinical data from our novel Dolaflexin platform demonstrating a favorable safety and tolerability profile and early signs of efficacy for XMT-1522 in heavily pre-treated patients who have exhausted available therapies,” said Anna Protopapas, President and CEO, Mersana Therapeutics. “These data support the further development of XMT-1522, and we look forward to continuing to evaluate its potential to serve the significant unmet needs of patients with HER2-expressing breast cancer, non-small cell lung cancer, and gastric cancer, who have limited treatment options.”